GlassScriptPhysician profile
Malcolm Eric Duncan
NPI 1033691746
$33,443.50
in general payments reported to CMS, 2019-2025
17 companies · $8,062 in 2025
The $8,062 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,326 · 2022: $1,191 · 2023: $5,535 · 2024: $17K · 2025: $8,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $9,319 · Travel and Lodging: $3,882 · Consulting Fee: $2,655 · Education: $80.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,989.25 |
| Food and Beverage | $9,318.55 |
| Travel and Lodging | $3,882.27 |
| Consulting Fee | $2,655.00 |
| Education | $80.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22,324.97 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $6,282.71 | 2021-2025 | Aristada, Aristada Initio, Lybalvi |
| Neurocrine Biosciences, INC. | $1,509.50 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $800.64 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $764.50 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $478.61 | 2021-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $417.03 | 2024-2025 | Cobenfy |
| Abbvie INC. | $254.32 | 2021-2025 | |
| Lundbeck LLC | $159.64 | 2021-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $159.50 | 2024 | Fanapt |
| Eisai INC. | $121.53 | 2021 | |
| Indivior INC. | $60.26 | 2022-2024 | Perseris |
| Alpha Cognition USA, INC. | $35.64 | 2025 | Zunveyl |
| Avanir Pharmaceuticals, INC. | $20.75 | 2022 | |
| Noven Therapeutics, LLC | $19.19 | 2023 | Secuado |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.79 | 2024 | Amyvid, Kisunla |
| Supernus Pharmaceuticals, INC. | $15.92 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.